Abstract
In this study 6,112 COPD patients were treated with salmeterol 50 μg bid, fluticason 500 μg bid, salmeterol/fluticason combination 50/500 μg bid (SFK) or placebo for 3 years. The primary effect parameter was mortality and 875 patients had died after 3 years. Hazard ratio for death for SFK compared with placebo was 0.825, 95% confidence interval 0.681-1.002, p=0.052, or an absolute risk reduction of 2.6%. Active treatment reduced exacerbations and improved quality of life and lung function. The risk of pneumonia was higher in the fluticason and SFK treated groups than in the placebo group.
| Translated title of the contribution | Salmeterol and fluticason and mortality in COPD patients |
|---|---|
| Original language | Danish |
| Pages (from-to) | 3198-3201 |
| Number of pages | 3 |
| Journal | Ugeskrift for laeger |
| Volume | 169 |
| Issue number | 38 |
| Publication status | Published - 17 Sept 2007 |
